NCT07308392

Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis.

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 108 (estimated)
• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Phase II clinical trial evaluating the efficacy and safety of HRS-7249 and SHR-1918 in patients with severe hypertriglyceridemia at high risk of acute pancreatitis

Conditions

• Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis

Interventions

Type	Name	Description
DRUG	HRS-7249 injection set	HRS-7249 injection set
DRUG	SHR-1918 injection set	SHR-1918 injection set
DRUG	HRS-7249 injection placebo set	HRS-7249 injection placebo set
DRUG	SHR-1918 injection placebo set	SHR-1918 injection placebo set

Timeline

• Start date: 2026-02-25
• Primary completion: 2027-06-01
• Completion: 2027-06-01
• First posted: 2025-12-29
• Last updated: 2026-03-03

Locations

1 site across 1 country: China